Menu Search
Equities

Amphastar Pharmaceuticals Inc

AMPH:NSQ

Amphastar Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)45.25
  • Today's Change0.70 / 1.57%
  • Shares traded67.78k
  • 1 Year change-19.27%
  • Beta0.8026
Data delayed at least 15 minutes, as of Nov 22 2024 15:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Amphastar Pharmaceuticals Inc grew revenues 29.14% from 498.99m to 644.40m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 50.51% net income growth from 91.39m to 137.55m.
Gross margin52.98%
Net profit margin21.95%
Operating margin29.61%
Return on assets10.28%
Return on equity23.85%
Return on investment11.88%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Amphastar Pharmaceuticals Inc fell by 11.80m. Cash Flow from Financing totalled 454.09m or 70.47% of revenues. In addition the company generated 183.50m in cash from operations while cash used for investing totalled 649.12m.
Cash flow per share4.02
Price/Cash flow per share10.21
Book value per share15.04
Tangible book value per share2.75
More ▼

Balance sheet in USDView more

Amphastar Pharmaceuticals Inc has a Debt to Total Capital ratio of 45.06%, a lower figure than the previous year's 107.24%.
Current ratio3.43
Quick ratio2.61
Total debt/total equity0.82
Total debt/total capital0.4506
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 48.88%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		17.33
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.